Growth Metrics

Pacira BioSciences (PCRX) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to $5.4 million.

  • Pacira BioSciences' Income towards Parent Company rose 10378.63% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 12362.81%. This contributed to the annual value of -$99.6 million for FY2024, which is 33730.19% down from last year.
  • Pacira BioSciences' Income towards Parent Company amounted to $5.4 million in Q3 2025, which was up 10378.63% from -$4.8 million recorded in Q2 2025.
  • Pacira BioSciences' Income towards Parent Company's 5-year high stood at $25.8 million during Q2 2023, with a 5-year trough of -$143.5 million in Q3 2024.
  • Over the past 5 years, Pacira BioSciences' median Income towards Parent Company value was $9.0 million (recorded in 2024), while the average stood at $296631.6.
  • Per our database at Business Quant, Pacira BioSciences' Income towards Parent Company surged by 166681.1% in 2023 and then plummeted by 142129.31% in 2024.
  • Pacira BioSciences' Income towards Parent Company (Quarter) stood at -$5.1 million in 2021, then tumbled by 96.92% to -$10.1 million in 2022, then skyrocketed by 346.19% to $24.9 million in 2023, then crashed by 35.5% to $16.0 million in 2024, then plummeted by 66.14% to $5.4 million in 2025.
  • Its Income towards Parent Company stands at $5.4 million for Q3 2025, versus -$4.8 million for Q2 2025 and $4.8 million for Q1 2025.